A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma - NCT00752570-(Clinical Trial 241861)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Greenville |
|
State:
|
|
SC |
| Zip Code: |
|
|
| Conditions: |
|
Cancer - Carcinoma - Colon Cancer - Colorectal Cancer - Gastric Cancer - Gastrointestinal Cancer - Metastases - Metastatic Cancer - Metastatic Colorectal Cancer - Oncology - Rectal Cancer |
| Purpose: |
|
This clinical trial will compare the efficacy and safety of the combination of AMG 386 and
FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the colon or rectum in patients who are
presenting with metastatic disease
- One and only one prior chemotherapy regimen for metastatic disease consisting of the
combination of a fluoropyrimidine-based chemotherapy and an oxaliplatin-based
chemotherapy. Prior adjuvant chemotherapy used prior to the onset of metastatic
disease is permitted
- At least one uni dimensionally measurable lesion per modified RECIST criteria. All
sites of disease must be evaluated <= 28 days before randomization
- Radiographically documented disease progression per modified RECIST criteria either
while receiving or <= 6 months after the last dose of prior chemotherapy regimen for
metastatic disease
- ECOG performance status of 0 or 1
- Man or woman >= 18 years of age
- Adequate end organ assessments by laboratory studies (hematological and chemistries)
- Life expectancy >= 3 months
Exclusion Criteria:
- Exclude subjects with a history of prior malignancy, except:
- Malignancy treated with curative intent and with no known active disease present
for >= 3 years before enrollment and felt to be at low risk for recurrence by
treating physician
- Adequately treated non-melanomatous skin cancer or lentigo maligna without
evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Prostatic intraepithelial neoplasia without evidence of prostate cancer
- Prior irinotecan therapy
- Systemic chemotherapy, hormonal therapy, or immunotherapy <= 21 days prior to
randomization
- Experimental or approved proteins/antibodies (eg, bevacizumab) <= 30 days prior to
randomization
- Clinically significant cardiac disease within 12 months prior to randomization,
including myocardial infarction, unstable angina, grade 2 or greater peripheral
vascular disease, cerebrovascular accident, transient ischemic attack, congestive
heart failure, or arrhythmias not controlled by outpatient medication, percutaneous
transluminal coronary angioplasty/stent
- Known allergy or hypersensitivity to irinotecan, 5 FU (known dihydropyrimidine
dehydrogenase deficiency) or leucovorin
- Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
(defined as >= CTC grade 2 [CTCAE version 3.0]) |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
August 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|